A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2011
This randomized, double-blind, placebo- and active-controlled, parallel group study will evaluate the safety and efficacy of RO4917838 (bitopertin) in patients with acute exacerbation of schizophrenia. Patients will be randomized to receive either RO4917838 10 mg or RO4917838 30 mg or olanzapine 15 mg or placebo orally daily for 4 weeks as inpatients, with a 4-week follow-up period.
Epistemonikos ID: ee8810f2ff88ec81d7e2e16165be38ff249d4811
First added on: May 06, 2024